Update on Japanese encephalitis vaccine for children --- United States, May 2011

Morbidity and Mortality Weekly Report

Volumn 60, Issue 20, 2011, Pages 664-665

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE;

ADOLESCENT; ANIMAL; ARTICLE; ASIA; CERCOPITHECUS; CHILD; CLINICAL TRIAL (TOPIC); CULTURE TECHNIQUE; DRUG APPROVAL; HEALTH CARE PERSONNEL; HUMAN; INFANT; INSECT BITE; JAPANESE ENCEPHALITIS; JAPANESE ENCEPHALITIS VIRUS; LICENSING; MOSQUITO; MOUSE; OFF LABEL DRUG USE; PRESCHOOL CHILD; RISK; TRAVEL; UNITED STATES; VERO CELL;

ADOLESCENT; ANIMALS; ASIA; CELL CULTURE TECHNIQUES; CERCOPITHECUS AETHIOPS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; CULICIDAE; DRUG APPROVAL; ENCEPHALITIS VIRUS, JAPANESE; ENCEPHALITIS, JAPANESE; HEALTH PERSONNEL; HUMANS; INFANT; INSECT BITES AND STINGS; JAPANESE ENCEPHALITIS VACCINES; LICENSURE; MICE; OFF-LABEL USE; RISK; TRAVEL; UNITED STATES; VACCINES, INACTIVATED; VERO CELLS;

EID: 79958249448     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (6)

1. Hills SL, Griggs AC, Fischer M. Japanese encephalitis in travelers from non-endemic countries, 1973-2008. Am J Trop Med Hyg 2010;82:930-6.
2. CDC. Japanese encephalitis in two children-United States, 2010. MMWR 2011;60:276-8.
3. CDC. Japanese encephalitis vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2010;59(No. RR-1).
4. CDC. Health information for international travel, 2010. Atlanta, GA: US Department of Health and Human Services, CDC; 2009. Available at http://wwwnc.cdc.gov/travel/yellowbook/2010/table-of-contents.htm. Accessed May 19, 2011.
5. Lindsey NP, Staples JE, Jones J, et al. Adverse event reports following Japanese encephalitis vaccination in the U.S., 2000-2009. Vaccine 2010;29:58-64.
6. Kaltenböck A, Dubischar-Kastner K, Schuller E, Datla M, Klade CS, Kishore TS. Immunogenicity and safety of Ixiaro (IC51) in a phase II study in healthy Indian children between 1 and 3 years of age. Vaccine 2010;28:834-9.